The in vitro activity of CGP 31608, a new penem, against aerobic and anaerobic organisms was evaluated and compared with those of other beta-lactams. CGP 31608 inhibited Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus mirabilis, Citrobacter diversus, and SalmoneUla, Shigella, Aeromonas, and Yersinia spp. with MICs for 50% of the strains (MIC50s) of 2 to 4 pg/mI and MIC90s of 4 ,ug/ml, compared with cefotaxime, ceftazidime, aztreonam, and imipenem MICs of <0.25 ,ug/ml. MIC90s were 8 ,ug/mi for Enterobacter species and C. freundii, for which other agents had MICs of 32 ,Ig/ml, except imipenem, which had equal activity. The MIC90 for Proteus vulgaris, MorganeUa morganii, Providencia stuartii, and Providencia rettgeri was 8 ,ug/ml, compared with <2 ,ug/mI shown by the other agents. Acinetobacter species resistant to other agents except imipenem were inhibited by 4 ,ug/ml, as were Pseudomonas aeruginosa, including piperacillin-, ceftazidime-, and gentamicin-resistant isolates. The MIC for P. cepacia, P. fluorescens, and P. acidovorans was s8 gig/mi, but that for P. maltophilia was .128 ,ug/ml. Hemolytic streptococci A, B, C, G, and F were inhibited by <1 ,ug/ml, but the MIC for Streptococcus faecalis was '32 ,ug/ml. MICs for Staphylococcus aureus methicillinsusceptible and -resistant strains were sl ,ug/ml, as were those for methicillin-susceptible and -resistant S. epidermidis. Bacteroidesfragiis and Clostridium species and Fusobacterium spp. were inhibited by s4 ,Ig/ml.
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CGP 31608 was not hydrolyzed by plasmid beta-lactamases TEM-1, TEM-2, SHV-1, PSE-1, OXA-2, PSE-4, or by S. aureus. Chromosomal beta-lactamases of type Ia in Enterobacter cloacae P99 and Morganella morganii, Ic in P. vulgaris, K-1 in K. oxytoca, and Id in P. aeruginosa also did not hydrolyze CGP 31608. It inhibited TEM-1, but the 50% inhibitory concentration was 14.2 ,ug/ml compared with 0.15 ,ug/ml for the P99 enzyme. CGP 31608 induced beta-lactamases in P. aeruginosa, E. cloacae, C. freundii and Providencia rettgeri, but there was no increase in MICs for the isolates and it did not select strains derepressed for beta-lactamase production.
Synergy of CGP 31608 and gentamicin was found against 90% P. aeruginosa, 60% Enterobacter cloacae, and 50% Serratia marcescens strains. No synergy was found with rifampin. A postantibiotic effect was found against E. coli.
Although penem antibiotics have been known since the pioneering chemical syntheses of Woodward (3, 16) , few agents of this class have achieved clinical success. Several penems have undergone preclinical investigation. These include SCH 29482, SCH 34343, FCE 22101, and FCE 22891 (1, 7, 10, 11, 15) . Penems and carbapenems, such as imipenem, have been shown to inhibit a broad range of microorganisms, depending upon the substituent side chains (2, 4, 5) . In general, the agents have been extremely stable against attack by beta-lactamases but are susceptible to hydrolysis by dehydropeptidases which are prese t in kidney, lung, and intestinal tissue of different animal sj-cies (5).
We investigated the activity of a new penem, CGP 31608, (SR,6S)-2-(1'-aminoalkyl)-6-(hydroxyalkyl)penem-3-carboxylic compound (6) (Fig. 1 ), in comparison with those of other beta-lactam agents currently available.
(This material was presented at the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 28 September to 1 October 1986.)
MATERIALS AND METHODS
CGP 31608 was provided by CIBA-GEIGY, Basel, Switzerland. All other agents were gifts from their manufactur-* Corresponding author.
ers. The organisms used were isolates from patients at hospitals in the Columbia University system, and included isolates were retained because of known beta-lactamase activity or resistance to beta-lactam antibiotics or both.
Antimicrobial susceptibility tests. Antimicrobial activity was measured by an agar dilution method with MuellerHinton agar unless otherwise specified. A final inoculum of 105 CFU was applied with a replicating device. Broth dilution tests were performed with 5 x 105 CFU in tubes containing 1 ml. Incubation of agar and broth test tubes was at 35°C for 18 h. The susceptibility of Neisseria and Haemophilus spp. was determined with chocolate Mueller-Hinton agar in the presence of 5% CO2. The susceptibility of streptococci was determined with Mueller-Hinton agar supplemented with 5% sheep blood, and the susceptibility of anaerobic species was determined with brucella agar supplemented with sheep blood, hemin, and vitamin K. Incubation of anaerobic cultures was for 48 h in GasPak jars (BBL Microbiological Systems, Cockeysville, Md.). The susceptibility of methicillin-resistant staphylococci was determined on Mueller-Hinton agar or broth supplemented with 5% NaCl; isolates for which the oxacillin MIC was >8 ,ug/ml were considered resistant. The MIC was defined as the lowest concentration of antibiotic that inhibited the development of visible growth on agar or in broth. The MBC was determined by subculture of 0.01 ml from clear tubes onto antibiotic-free agar plates which indicated a 99.9% reduction in CFU. All tests were run with control strains from the American Type Culture Collection, Rockville, Md.
Beta-lactamase assays and inhibition studies. The presence of beta-lactamases in the clinical isolates was determined by the nitrocefin assay (9) . Enzymes used to analyze the stability of CGP 31608 and other agents were prepared as described previously (9) . The beta-lactamase stability was determined by spectrophotometric assay as described previously (9) and by use of a microbiological assay with Pseudomonas aeruginosa as the assay organism (9) . Inhibition assays were performed with nitrocefin as substrate and by varying the concentrations of different inhibitors used to calculate 50% inhibitory (150) concentrations.
Induction of beta-lactamases. One strain each of P. aeruginosa, Enterobacter cloacae, Citrobacter freundii, and Providencia rettgeri were grown overnight in broth and diluted 100-fold to achieve exponential growth. During incubation at 37°C, inducers were added at concentrations equal to one-fourth the MIC, one-half the MIC, and the MIC, and incubation was continued for 2 h. Bacteria were harvested by centrifugation, washed in 0.05 M potassium phosphate buffer (pH 7), and subsequently disrupted by sonication. Cellular debris were removed by centrifugation, and the samples were dialyzed at 4°C for 24 h against phosphate buffer. Beta-lactamase activity was determined by using nitrocefin as substrate, with activity based on A. hydrophilaa (10) Y. enterocoliticaa (10) H. influenzaea (15) N. gonorrhoeaea (15) B. catarrhalisa (10) P. aeruginosaa (57) The effect of serum upon the activity of CGP 31608 was determined for two isolates each of S. aureus, E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa. In 50% normal human serum, the MICs and MBCs were identical or within a factor 2 lower or higher than the MICs and MBCs determined in Mueller-Hinton broth. For the same strains, the MICs determined in sterile filtered urine (pH 5.5) were within a factor 2 of the MICs determined in broth (Table 4) .
Permeability studies. The role of permeability in the activity of CGP 31608 was analyzed by using beta-lactampermeable strains of P. aeruginosa and E. coli obtained from Zimmermann (17) and Richmond et al,, respectively (12). For P. aeruginosa, there was a fourfold difference in CGP 31608 MICs between the parent and the mutant (Table 5) . MICs for the permeable E. coli strains were the same as that for the parent strain.
Activity against strains possessing characterized betalactamases. At 4 ,ug/ml, CGP 31608 inhibited strains of P.
aeruginosa which contained PSE-1, PSE-2, PSE-3, and PSE-4 beta-lactamases. In contrast, the cefotaxime MICs exceeded 64 ,ug/ml for these isolates, and the MIC of cefoperazone for the PSE-4-containing strain was 128 ,ug/ml. CGP 31608 had an MIC of 4 ,ug/ml for E. cloacae P99, whereas the MICs of cefotaxime, ceftazidime, and aztreonam exceeded 32 ,ug/ml. The K. oxytoca containing the K-1 beta-lactamase for which the aztreonam MIC was 32 ,ug/ml was inhibited by 4 ,ug of CGP 31608 per ml, and an E. coli that had a high copy number of the plasmid coding for TEM-2 showed a cefoperazone MIC of >128 ,ug/ml but was inhibited by 4 ,ug of CGP 31608 per ml. Beta-lactamase stability and inhibitory activity. CGP 31608 was not hydrolyzed by the majority of plasmid and chromosomal beta-lactamases (Table 6 ). The Vma, for cephaloridine with these enzymes ranged from 15 to 7,560 ,umol/min per ,ug of protein.
CGP 31608 inhibited the hydrolysis of nitrocefin by a variety of beta-lactamases (Table 7) . It showed poor inhibition of the K-1, PSE-1, and PSE-4 beta-lactamases. CGP 31608 was an effective inhibitor of the chromosomal type Ia P99 beta-lactamase compared with cefotaxime and imipenem but a much less effective inhibitor of TEM-1, the plasmid enzyme, than clavulanic acid (Table 8) .
Beta-lactamase induction. The effect of exposure to CGP 31608 of single isolates of P. aeruginosa, E. cloacae, C. freundii, and Providencia rettgeri was determined. The beta-lactamase activity was determined by the nitrocefin assay (Table 9 ). There was an increase in beta-lactamase production. These organisms were tested against CGP 31608 and imipenem (Table 10 ). The MICs of both CGP 31608 and imipenem remained identical in comparison with the increase in the MIC of the selecting agent.
Killing data and postantibiotic suppression. The killing activity of CGP 31608 was studied with a beta-lactamaseproducing E. coli strain resistant to ampicillin, cefazolin, cefoperazone, and trimethoprim and with a P. aeruginosa strain resistant to carbenicillin and gentamicin. The CGP 31608 MIC was 4 ,ug/ml and the MBC was 8 p.g/ml; the imipenem MIC was 0.25 ,ug/ml and the MBC was 0.5 jig/ml for the E. coli strain. Exposure for 1 h to CGP 31608 produced a decrease in CFU comparable to the decrease with imipenem (Table 11) . CGP 31608 produced a kill effect at a concentration only twice the MBC, which was comparable to that with imipenem 30-fold above the MBC. A 2-h exposure at 15 ,ug/ml caused a major decrease in CFU for CGP 31608 and imipenem. With the P. aeruginosa strain for which the CGP 31608 MBC was 16 ,ug/ml and the imipenem MBC was 4 ,ug/ml, there were equal decreases in CFU for CGP 31608 compared with imipenem.
The postantibiotic effect (PAE) of CGP 31608 and imipenem were also studied for the above organisms. A PAE was found for E. coli (Table 12) . We did not find a PAE for the P. aeruginosa strain when the exposure was for 1 h, and a short PAE compared with the PAE for imipenem.
Synergy studies. The effect of combination of CGP 31608 and azlocillin, gentamicin, rifampin, and ciprofloxacin was studied with P. aeruginosa, E. cloacae, and S. marcescens (Table 13) . Antagonism was seen only for azlocillin with one S. marcescens and one P. aeruginosa strain. Gentamicin was most likely to act synergistically with CGP 31608, ciprofloxacin was less likely, and rifampin and azlocillin were primarily indifferent, as tested against P. aeruginosa and S. marcescens.
DISCUSSION
The first penem was synthesized in 1975 (3, 16) , but the compound was destroyed by beta-lactamases, probably be- 16 ,g/mi; imipenem: MBC, 4 ,g/mi.
cause of the type of acyl side chain present on C-6. Penems were conceived as compounds that would combine properties of penams and cephems, in which the reactivity produced by the double bond between C-3 and C-4 of the cephem would be present in a five-membered ring. The knowledge gained from the analysis of the naturally occurring carbapenem thienamycin showed that introduction of a hydroxyethyl substituent at C-6 would yield a chemically stable, beta-lactamase-resistant agent (5, 8) .
To date, only a few penems have been extensively investigated despite the plethora of compounds found in the patent literature. The well-known penems are SCH 29482, SCH 34343, FCE 22101, and FCE 22891 (1, 4, 7, 10, 11, 15) . These agents have been demonstrated to inhibit a wide range of aerobic and anaerobic organisms (1, 7, 10, 11, 15) but lack the activity against P. aeruginosa which the carbapenem imipenem possesses. This study illustrates that CGP 31608 has an extremely broad spectrum of antibacterial activity, inhibiting most members of the family Enterobacteriaceae at s4 jig/ml, including species resistant to ampicillin, cefazolin, cefoperazone, and piperacillin. It also has excellent activity (MIC%0, 4 ,ug/ml) against P. aeruginosa, including selected isolates resistant to gentamicin, amikacin, piperacillin, ceftazidime, and aztreonam.
In general, the MIC90s of cefotaxime, ceftazidime, and aztreonam for the highly susceptible members of the family Enterobacteriaceae are lower (0.25 ,.g/ml) than those of CGP 31608 (2 to 4 jig/ml), and imipenem usually is fourfold more active than CGP 31608. Conversely, CGP 31608 and imipenem both inhibit isolates of E. cloacae, C. freundii, S. marcescens, and P. aeruginosa at 4 to 8 ,ug/ml, although the above agents have MICs in the range of 16 to 64 ,ug/ml.
The gram-positive activity of CGP 31608 is impressive and comparable to the published activity of cephalosporins and isoxazolyl penicillins against staphylococci and streptococci (4), and CGP 31608 is more active than cefotaxime against staphylococci and minimally less active against streptococci. Of particular note is its activity against methicillin-resistant S. aureus and S. epidermidis strains. It inhibits isolates resistant to imipenem. This is a new aspect of these agents. The mechanism is unknown and could be due to failure to induce a new penicillin-binding protein 2' or to affinity for the new enzymes. Studies are in progress to determine this. Unlike imipenem, CGP 31608 does not inhibit enterococci, S. faecalis, or S. faecium, and the explanation for this is unknown.
Similarly to the other penems and to carbapenems, CGP 31608 has excellent in vitro activity against anaerobic cocci and bacilli and inhibits isolates resistant to cefoxitin, cefotaxime, and piperacillin. As with all beta-lactams, MICs against certain anaerobes, C. difficile and Bacteroides theataiotaomicron, are higher, i.e., 4 to 8 ,ug/ml, than against C. perfringens and B. fragilis.
CGP 31608 has excellent beta-lactamase stability with both chromosomal and plasmid enzymes. Although it induces beta-lactamase activity as do other penems, cephamycins, carbapenems and clavams, the induced strains remain susceptible to the compound. Furthermore, CGP 31608 does not select isolates which constitutively produce high levels of beta-lactamase as do certain cephalosporins (14) . CGP 31608 inhibits beta-lactamase-producing isolates selected by exposure to other beta-lactams.
CGP 31608 showed a PAE for E. coli at concentrations that would be achieved in humans (0. Zak, personal communication), but the effect was minor with P. aeruginosa. Higher concentrations may demonstrate the effect similar to that noted with imipenem tested against P. aeruginosa. It is also possible that a study of a larger number of isolates will show the effect.
Overall, these studies demonstrate the excellent in vitro properties of this novel penem. Further pharmacological and clinical studies will establish the clinical utility of this agent in comparison with other beta-lactams. Clearly, this penem has very impressive in vitro activity against staphylococci, including methicillin-resistant bacteria, and against P. aeruginosa, and this would make it of interest in an era of increased problems with these species.
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